Search

everythinglearnresearchcommunity

for

Search:↓

A 45-year-old male successfully slowed hair loss using Nizoral and low-level laser therapy (LLLT) but cannot use Minoxidil, finasteride, or dutasteride for medical reasons. He seeks suggestions for hair regrowth options.

Low-level laser therapy hats for hair loss, with skepticism about their effectiveness and cost. Users suggest trying affordable alternatives instead of expensive options.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

A new hair loss lotion by Dr. Brotzu, expected to regrow up to 5 years of lost hair, is set to be released by Fidia Farmaceutici. It claims to work like minoxidil and finasteride without side effects, but skepticism exists due to its classification as a cosmetic product.

A user is seeking advice on purchasing RU58841 from Biolab Shop in Poland and is looking for trustworthy sources that deliver to Germany from Europe or China. They are interested in the product's composition and user experiences.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

Diffuse thinners find shopping challenging due to harsh overhead lighting, but H&M's side lighting in fitting rooms is more flattering. Many users humorously suggest banning overhead lighting to improve the shopping experience.

This user has conducted data scraping of 365 Reddit posts on the hairloss drug Pyrilutamide over the last year to analyse efficacy and side effects. The findings, which are available in a 19 page report with graphs, suggest that 22% of Pyrilutamide users experience positive results while 63% experience symptoms. A larger analytics project is proposed for other drugs with enough demand.

The effects of Pyrilutamide, a hair loss treatment that is being tested for June/July; and reports from people who have experienced side effects similar to those of RU58841, suggesting they may have been sold an incorrect product from their supplier.

Laritelle shampoo is questioned for its effectiveness in reducing hair loss and rejuvenating hair follicles. A user dismisses it as ineffective.

Musely sells a hair topical solution containing latanoprost, which degrades in 6 weeks, yet they market it as a 3-month supply. Concerns are raised about the product's effectiveness and the company's sales strategy.

Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.

The conversation is about the stability of pyrilutamide in different solutions. The user is asking if a 70/30 ethanol/pg solution with 4% water will degrade pyrilutamide.

Combining microneedling with Low Level Laser Therapy (LLLT) for hair growth, with discussions on device legitimacy and effectiveness. Alternatives like PEMF and the use of oral and topical treatments such as dutasteride, minoxidil, and finasteride are also considered.

The conversation is about skepticism towards the hair loss treatments RU58841 and Pyrilutamide, with users discussing the lack of human testing for RU58841 and the ongoing trials for Pyrilutamide. Some users believe RU58841 has more anecdotal success, while others highlight Pyrilutamide's current research progress.

The conversation confirms that to make a 5% RU58841 solution, 1.5 grams should be added to 30 mL of KB Solution. The discussion involves calculating the correct dosage for hair loss treatment.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

Breezula is being sold at Anagen Inc and Universal Labs, and users are discussing their experiences and results with it. There is also interest in the formulation process and inquiries about PP405.

Hair is growing faster after 2 weeks of using topical vitamin D3 in alcohol/oil. The user plans to continue the experiment for 3 months before giving a full review.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

A user is seeking advice on ordering ethanol in the UK to use with topical finasteride, considering switching from isopropyl alcohol. They mention the possibility of purchasing 99.8% ethanol from eBay's 6 Science shop.

Oleic acid and ethanol are being considered for hair regrowth, with some users planning to self-experiment. There is skepticism about their effectiveness, and ongoing use of treatments like finasteride and minoxidil is mentioned.

The user tried a product labeled as PP405 from Umbrella Labs for hair loss but saw no changes, and it was revealed to be a fake or misidentified product. The user is also using finasteride, minoxidil, and other treatments but is still experiencing hairline issues.

A 40-year-old male using microneedling, low-level laser therapy (LLT), and rosemary oil for hair regrowth. No finasteride or minoxidil is used.

Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.